FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Phase 2

Terminated

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

Interventions: Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: umbilical cord blood transplantation
Radiation: total body irradiation

First Posted Date: 2008-07-22

Last Posted Date: 2017-06-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00719849

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Phase 2

Completed

Conditions: Acute Biphenotypic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Lymphoplasmacytic Lymphoma
Mantle Cell Lymphoma
Myelodysplastic Syndrome
Non-Hodgkin Lymphoma
Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cyclosporine
Procedure: Double-Unit Umbilical Cord Blood Transplantation
Drug: Fludarabine
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation
Drug: Thiotepa

First Posted Date: 2008-07-22

Last Posted Date: 2025-03-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 135

Registration Number: NCT00719888

Locations: 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Phase 2

Active, not recruiting

Conditions: Multiple Sclerosis Transplant
Chronic Inflammatory Demyelinating Polyneuropathy
Myasthenia Gravis
Rasmussen Subacute Encephalitis
Neurologic Autoimmune Disease
CIDP Transplant
Central Nervous System Vasculitis
Autoimmune Disease
Autologous Transplant Autoimmune
MS Stem Cell Transplant

Interventions: Biological: Anti-Thymocyte Globulin
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Prednisone
Procedure: Syngeneic Bone Marrow Transplantation

First Posted Date: 2008-07-16

Last Posted Date: 2025-02-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00716066

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Swedish Medical Center-First Hill, Seattle, Washington, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

Move and Moderate in Balance

Not Applicable

Completed

Conditions: Overweight
Obesity
Sedentary

First Posted Date: 2008-07-15

Last Posted Date: 2011-12-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00715130

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Carotene and Retinol Efficacy Trial

Phase 4

Completed

Conditions: Lung Cancer

Interventions: Drug: Beta Carotene and Retinol
Other: Placebo

First Posted Date: 2008-07-10

Last Posted Date: 2012-09-26

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18314

Registration Number: NCT00712647

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Phase 1

Completed

Conditions: Philadelphia Positive Adult Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Childhood Acute Lymphoblastic Leukemia
Accelerated Phase Chronic Myelogenous Leukemia
Childhood Acute Lymphoblastic Leukemia in Remission
Childhood Chronic Myelogenous Leukemia
Relapsing Chronic Myelogenous Leukemia
Untreated Adult Acute Lymphoblastic Leukemia
Untreated Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: nilotinib
Drug: imatinib mesylate
Other: pharmacological study

First Posted Date: 2008-06-20

Last Posted Date: 2017-08-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00702403

Locations: 🇺🇸
H Lee Moffitt Cancer Center and Research Institute Phase 2 Consortium, Tampa, Florida, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States

and more 2 locations

Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Untreated Adult Acute Myeloid Leukemia
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)

Interventions: Drug: gemtuzumab ozogamicin
Drug: vorinostat
Other: laboratory biomarker analysis

First Posted Date: 2008-05-07

Last Posted Date: 2017-06-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00673153

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 1 locations

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Phase 1

Terminated

Conditions: Gliosarcoma
Glioblastoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Biological: Filgrastim
Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Drug: O6-Benzylguanine
Drug: Plerixafor
Radiation: Proton Beam Radiation Therapy
Drug: Temozolomide